AAIPharma and Cambridge Major Laboratories Name CEOBy
AAIPharma Services Corp., a provider of pharmaceutical analytical testing, product development, and manufacturing services, and Cambridge Major Laboratories, Inc., a provider of pharmaceutical development and manufacturing services for active pharmaceutical ingredients, have appointed Stephan Kutzer, PhD, as chief executive officer (CEO), effective August 1, 2014.
AAIPharma and Cambridge Major Laboratories merged in October 2013 and Patrick Walsh, formerly CEO of AAIPharma, was named CEO of the merged company. Walsh resigned as CEO of the merged company in April 2014, and Susan Nestegard was appointed interim CEO.
Most recently, Kutzer served as chief operating officer of Lonza, Inc. Since 2003, he has also served as chief operating officer and/or president of several divisions, including Lonza Pharma Biotech Division, Lonza Custom Manufacturing, Lonza Biopharmaceuticals, and Lonza Performance Chemicals. From 1999 to 2002, he served as site director and vice president of operations of Lonza's Bayport, Texas facilities, and in 1999, he was director of process improvement at Lonza Guangzhou Ltd. Guangzhou, PR China. At Lonza Visp, he was production and plant manager (1998) and assistant production manager (1996) of nicotinates. He holds a master's degree in chemical and process engineering and a PhD in engineering sciences (chemical engineering) from the Technical University of Munich, Germany.